Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M14.7Revenue $M0.1Net Margin (%)-682.6Altman Z-Score-313.2
Enterprise Value $M14.1EPS $-0.0Operating Margin %-737.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-741.0Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.8Cash flow > EarningsY
Price/Sales79.65-y EBITDA Growth Rate %7.4Current Ratio0.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-397.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-229.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M147ROIC % (ttm)-297.2Gross Margin Increase y-yY

Gurus Latest Trades with SGBI

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

SGBI is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SGBI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MCCANNA LAWRENCE EDirector 2013-08-13Sell3,125$24.78-99.6 view
FLEING JOACHIMCFO, Secretary 2013-02-26Buy11,500$0.33-69.7 view
SMITH ROBERT EDirector, 10% Owner 2012-06-08Buy22,500$7.96-98.74 view
FLEING JOACHIMCFO, Secretary 2012-04-23Sell10,000$0.53-81.13 view
FLEING JOACHIMCFO, Secretary 2012-04-02Sell3,100$0.75-86.67 view
FLEING JOACHIMCFO, Secretary 2012-03-30Sell50,000$0.61-83.61 view
FLEING JOACHIMCFO, Secretary 2012-03-30Sell50,000$0.61-83.61 view
SMITH ROBERT EDirector, 10% Owner 2012-02-21Buy85,000$11.58-99.14 view
FLEING JOACHIMCFO, Secretary 2011-12-08Buy150,000$0.2-50 view
LEADER MARTIN RDirector 2011-09-16Buy668$8.38-98.81 view

Press Releases about SGBI :

    Quarterly/Annual Reports about SGBI:

    News about SGBI:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    10-Q for Sangui Biotech International, Inc. May 19 2015
    SANGUI BIOTECH INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report May 15 2015
    Sangui BioTech: Lower Revenues in the Third Quarter May 15 2015
    Sangui BioTech International Secures Financial Framework of $5 Million over Three Years May 12 2015
    10-Q/A for Sangui Biotech International, Inc. May 07 2015
    SANGUI BIOTECH INTERNATIONAL INC Financials Mar 20 2015
    Sangui BioTech: Series of Preclinical Trials Concluded Successfully Mar 18 2015
    SANGUI BIOTECH INTERNATIONAL INC Files SEC form 10-Q/A, Quarterly Report Mar 13 2015
    SANGUI BIOTECH INTERNATIONAL INC Files SEC form 10-Q/A, Quarterly Report Mar 09 2015
    SANGUI BIOTECH INTERNATIONAL INC Files SEC form 10-Q/A, Quarterly Report Mar 03 2015
    SANGUI BIOTECH INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Feb 12 2015
    Sangui BioTech: Revenues Slightly Improved in the First Half of the 2015 Financial Year Feb 12 2015
    SanguiBioTech: SastoMed Closes Contracts with Distribution Partners in Six Additional Markets in... Feb 03 2015
    SanguiBioTech Yields Revenues of over USD31,000 in Q2 2015 According to Preliminary Figures Jan 28 2015
    SANGUI BIOTECH INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Nov 13 2014
    Sangui BioTech: Revenues Improved in the First Quarter of the 2015 Financial Year Nov 13 2014
    Sangui Biotech: Preclinical Trials Demonstrate: Sangui Hemoglobin Preparation Improves Oxygen Supply... Nov 11 2014
    Sangui BioTech International officially approved as trading on OTCQB Nov 06 2014
    Sangui BioTech: Laboratorios Silanes Start Marketing Granulox in Mexico Nov 03 2014
    Sangui BioTech Yields Revenues of over USD70,000 in Q1 2015 According to Preliminary Figures Oct 07 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK